carlyle sk capital - Search News

bluebird bio sells itself to Carlyle, SK Capital

Bluebird Bio to Be Acquired by Carlyle Group, SK Capital

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

STAT · 21h

Bluebird Bio sells itself to Carlyle, SK Capital for less than $30 million

Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million.

Business Insider · 22h

Bluebird Bio to be acquired by Carlyle, SK Capital for $3.00 per share

Bluebird Bio (BLUE) announced that it has entered into a definitive agreement to be acquired by funds managed by Carlyle (CG) and SK Capital

BioPharma Dive19h

Bluebird, at risk of default, agrees to take-private deal

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...

21h

Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

22h

What's Going On With Gene Therapy Company Bluebird Bio Stock Today?

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

TMCnet21h

BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of bluebird bio, Inc. (NASDAQ: BLUE) to Carlyle Group and SK Capital Partners, LP is fair to bluebird shareholders.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results